Buy, Sell or Hold: Teva Pharmaceutical (TEVA-N) — Stock Predictions at Stockchase

skip to content

Home Daily Stock Opinions and Ratings Teva Pharmaceutical (TEVA-N)

NYSE:TEVA

16.80

0.65 (3.72%) 1d

Related posts

Alibaba IPO the biggest of 2019 as U.S. Attorney subpoenas big pharma

Investor Insights

This summary was created by AI, based on 1 opinions in the last 12 months.

The reviews for Teva Pharmaceutical highlight the stock's low price and current momentum, but experts agree that these may be its only positive qualities. Overall, the stock has failed to impress reviewers and has not shown significant potential in their eyes. No standout qualities or compelling reasons to invest were mentioned. The consensus on the stock is underwhelming, with experts expressing a lack of interest or confidence in its potential. This indicates a lack of enthusiasm or optimism for the stock among industry professionals.

Consensus

Underwhelming

Valuation

Undervalued

Similar

Johnson & Johnson, JNJ-N

DON'T BUY

It's cheap and has momentum, but that's all it has now. It never grabbed him.

biotechnology / pharmaceutical

DON'T BUY

Massive share price appreciation not sustainable.
Large debt load presents difficulties.
Does not own shares.
Would not recommend buying at this time.

biotechnology / pharmaceutical

BUY ON WEAKNESS

Has owned company for a long period of time in the past. Previous reasons for owning stock not present anymore. Waiting to see if new drugs are invented/patented.

biotechnology / pharmaceutical

DON'T BUY

He's put the white flag up on this one. It's about macro interest rates, currency moves. Don't waste your time with these story stocks. His model price is $18.80, and it could have all the fundamentals, but the macro waves swamp the boat. Go with the big names.

biotechnology / pharmaceutical

DON'T BUY

Tends to avoid companies with a ton of debt. Management missteps, and investors are paying for those. In the depths of a tough turnaround. He'd rather own a VTRS, where the debt is manageable, balance sheet's in better shape, with a better growth trajectory.

biotechnology / pharmaceutical

DON'T BUY

Involved in the opiate crisis. Balance sheet is weak. Overall topline growth is low. Stay away. A lot of problems still to overcome.

biotechnology / pharmaceutical

DON'T BUY

Doesn't offer growth. The stock is weak and will stay weak.

biotechnology / pharmaceutical

BUY

It's time to get back in. They all went crazy and then slid on sympathy when valiant went bust. There is tremendous value here. His model price is $21.26 or 63% upside. They presented earnings and the balance sheet looks great.

biotechnology / pharmaceutical

HOLD

Generic brand companies like Teva have struggled in the last 5 years has they competed with each others. Pfizer is in the process of buying one of their competitors and the Pfizer stock dropped 5$ on the announcement. Doesn't own Teva, purchased United Heatlth recently. You can hold but it's not a name he would hold due to the risk and they have no value added.

biotechnology / pharmaceutical

DON'T BUY

They went from an in incredibly well managed drug company and then management decided to develop their own drugs and make mistakes. It is difficult to unwind these problems. Turning around a company like this will be difficult because of the debt. This is a highly speculative stock.

biotechnology / pharmaceutical

DON'T BUY

He sold it at a 50% loss due to price declines in generic drugs. That deflation has decreased lately, which is sort of good news. One of their big drugs came off patent, too.

biotechnology / pharmaceutical

DON'T BUY

A generic drug company that has had troubled times as pricing is becoming very competitive. Buyers are consolidating and squeezing margins. They have a MS drug that was a market leader, but now there are others competing. He would rather own brand name drug companies that can become leaders in their field.

biotechnology / pharmaceutical

DON'T BUY

It has done very well. But they made a huge acquisitions three years ago, taking on a lot of debt. They went through several CEOs. The generic drug space is tough and competitive. Generic drug pricing is limited as we head towards a U.S. election; generics are a target of politicians. Also, there are many lawsuits in the generic drug industry. Generics should do better after the election.

biotechnology / pharmaceutical

DON'T BUY

He is more content owning the major pharma versus generic producers. The competition in the space too intense. They have been involved in the manufacturing of opiod based drugs, which could come under regulatory pressure.

biotechnology / pharmaceutical

COMMENT

There is hope for it. Good news is the generic price declines have subsided, but "less declines" is not where he wants to be right now. Challenged in the next 12-18 months. Could go to low 20s, but structural headwinds for the business.

biotechnology / pharmaceutical

Showing 1 to 15 of 272 entries

«
‹
1
2
3
4
5
›
»

Next Page

Teva Pharmaceutical(TEVA-N) Rating

Ranking : 3 out of 5

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 1

Total Signals / Votes : 1

Stockchase rating for Teva Pharmaceutical is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Teva Pharmaceutical(TEVA-N) Frequently Asked Questions

What is Teva Pharmaceutical stock symbol?

Teva Pharmaceutical is a American stock, trading under the symbol TEVA-N on the New York Stock Exchange (TEVA). It is usually referred to as NYSE:TEVA or TEVA-N

Is Teva Pharmaceutical a buy or a sell?

In the last year, 1 stock analyst published opinions about TEVA-N. 0 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Teva Pharmaceutical.

Is Teva Pharmaceutical a good investment or a top pick?

Teva Pharmaceutical was recommended as a Top Pick by on . Read the latest stock experts ratings for Teva Pharmaceutical.

Why is Teva Pharmaceutical stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Teva Pharmaceutical worth watching?

1 stock analyst on Stockchase covered Teva Pharmaceutical In the last year. It is a trending stock that is worth watching.

What is Teva Pharmaceutical stock price?

On 2024-12-12, Teva Pharmaceutical (TEVA-N) stock closed at a price of $16.8.

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.

© Stockchase Inc.